Suppr超能文献

[现代制药科学技术史略(第4部分)。二战后50年]

[Historical sketch of modern pharmaceutical science and technology (Part 4). Post World War II 50 years].

作者信息

Yamakawa K

机构信息

Faculty of Pharmaceutical Sciences, Science University of Tokyo.

出版信息

Yakushigaku Zasshi. 1995;30(2):75-90.

Abstract

A short history of the pharmaceutical science and technology, postwar 50 years is divided into nine sections for the purpose of discussion. 1. Japan's postwar rehabilitation, Japanese pharmaceutical industries and newly developed pharmaceutical sciences and technologies. In 1945, the Japanese pharmaceutical industry was reconstructed. Production of penicillin was carried out with the strong support of the U.S. Occupation Forces. New sciences in pharmacy (biochemistry, biopharmacy, pharmacology, microbiology, physical chemistry, etc.) were introduced in this period. 2. Introduction age of foreign new drugs and technology (1951 to 1960s). Japan gained independence in 1951. Japanese pharmaceutical companies imported many new drugs and new pharmaceutical technologies from the U.S.A. and European countries in this period. Then, these companies were reconstruction rapidly. However, consequently Japanese pharmaceutical companies were formed as an imitation industry. 3. Rapid economic growth period for pharmaceutical companies (1956 to 1970s). In this period, many Japanese pharmaceutical companies grew rapidly at an annual rate of 15-20% over a period of 15 years, especially with regard to the production of active vitamin B1 analog drugs and some OTC (public health drugs). Some major companies made large profits, which were used to construct research facilities. 4. Problems for the harmful effects of medicines and its ethical responsibility. In the 1970s, many public toxic and harmful effects of medicines were caused, especially SMON's disease. In this time, many pharmaceutical companies changed to its security got development of ethical drugs. 5. Self development of new drugs and administration of pharmaceutical rules (1970s). During the 1970s, many pharmaceutical laws (GLP, GCP, GMP, GPMSP etc.) were enacted by the Ministry of Health and Welfare. In 1976, the Japanese Pharmaceutical Affairs Law was revised, which set forth standards regarding the efficacy and safety of ethical drugs and re-evaluation of drugs. Many facilities were built for the purpose of ensuring efficacy and safety, as shwon in Table 1. 6. Problems of Intellectual Property and followed the revisionist line of research and development for new ethical drugs. In 1976, Japanese pharmaceutical companies ceased to be an imitation industry, and increased research for the development of new drugs. 7. Pharmaceutical science and technology innovation (After 1985). Many of the pharmaceutical innovations during this period were as follows: 7.1) Technology innovation for evaluation of drug efficacy; 7.2) 1st to 3rd medical diagnostic technology innovations; 7.3) medical analytical methods and spectrometry technologies; 7.4) Computer-aided drug-design technology and drug information technology innovation; and 7.5) Drug delivery system and treatment drugs. 8. Recent research and development of new ethical drugs in Japan (1970 to 1995). Cephalosporine type beta-lactams (cefazolin, cefametazole, furomoxef, cefdinir), new quinolones (norfloxcin, ofloxacin, tosfloxcin), H1-Blockers (famotidine), Ca-antagonists (diltiazem, nicardipine), and other new drugs (pravastatine, taclolimus, leuprine) etc. came onto the market. 9. International Harmonization Age and Review toward 21 century. The rapid development and globalization of the pharmaceutical market has promoted international harmonization and rationalization of pharmaceutical regulatory affairs. In 1990, the Japan Pharmaceutical Manufacturers Association published a report toward 21 century, which described practical plans.

摘要

战后50年的制药科学技术简史分为九个部分进行讨论。1. 日本战后复兴、日本制药行业以及新发展的制药科学技术。1945年,日本制药行业进行了重建。在美国占领军的大力支持下开展了青霉素生产。这一时期引入了药学领域的新科学(生物化学、生物药剂学、药理学、微生物学、物理化学等)。2. 国外新药与技术引进时代(1951年至20世纪60年代)。日本于1951年获得独立。在此期间,日本制药公司从美国和欧洲国家进口了许多新药和新制药技术。随后,这些公司迅速重建。然而,结果是日本制药公司形成了一个仿制药行业。3. 制药公司的经济快速增长期(1956年至20世纪70年代)。在这一时期,许多日本制药公司在15年的时间里以每年15% - 20%的速度快速增长,尤其在活性维生素B1类似物药物和一些非处方药(大众健康药物)的生产方面。一些大公司获得了巨额利润,这些利润被用于建设研究设施。4. 药品有害影响问题及其伦理责任。20世纪70年代,出现了许多药品的公共毒性和有害影响,尤其是氯碘羟喹病。此时,许多制药公司转向开发安全性更高的处方药。5. 新药自主研发与制药法规管理(20世纪70年代)。20世纪70年代,厚生省颁布了许多制药法规(GLP、GCP、GMP、GPMSP等)。1976年,修订了《日本药事法》,该法规定了处方药疗效和安全性的标准以及药品再评价。为确保疗效和安全性建设了许多设施,如表1所示。6. 知识产权问题以及随之而来的新处方药研发路线修正。1976年,日本制药公司不再是仿制药行业,并加大了新药研发力度。7. 制药科学技术创新(1985年之后)。这一时期的许多制药创新如下:7.1)药物疗效评估技术创新;7.2)第一至第三代医学诊断技术创新;7.3)医学分析方法和光谱技术;7.4)计算机辅助药物设计技术和药物信息技术创新;以及7.5)药物递送系统和治疗药物。8. 日本近期新处方药研发(1970年至1995年)。头孢菌素类β - 内酰胺抗生素(头孢唑林、头孢美唑、呋罗沙星、头孢地尼)、新喹诺酮类药物(诺氟沙星、氧氟沙星、托氟沙星)、H1受体阻滞剂(法莫替丁)、钙拮抗剂(地尔硫䓬、尼卡地平)以及其他新药(普伐他汀、他克莫司、亮丙瑞林)等上市。9. 国际协调时代与面向2l世纪的审视。制药市场的快速发展和全球化推动了制药监管事务的国际协调与合理化。1990年,日本制药工业协会发布了一份面向21世纪的报告,其中描述了实际计划。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验